Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31045431 | 1.00 | ALDH1A1 (0.71) | ALDH1A1CYP3A4TSHRTDP1HSD17B10 | |
| SCHEMBL8868058 | 0.85 | ALDH1A1 (0.67) | ALDH1A1CYP3A4TSHRTDP1HSD17B10 | |
| SCHEMBL2888639 | 0.84 | GAA (0.71) | ALDH1A1CYP3A4TSHRTDP1GAA | |
| SCHEMBL30541678 | 0.83 | ALDH1A1 (1.00) | ALDH1A1CYP3A4TSHRTDP1HSD17B10 | |
| SCHEMBL273470 | 0.83 | ALDH1A1 (1.00) | ALDH1A1CYP3A4TSHRTDP1HSD17B10 | |
| SCHEMBL9516946 | 0.83 | ALDH1A1 (0.77) | ALDH1A1CYP3A4TSHRTDP1HSD17B10 | |
| SCHEMBL19921255 | 0.82 | ALDH1A1 (0.62) | ALDH1A1CYP3A4TSHRTDP1HSD17B10 | |
| SCHEMBL2040802 | 0.82 | ALDH1A1 (0.74) | ALDH1A1CYP3A4TSHRTDP1HSD17B10 | |
| SCHEMBL5831938 | 0.82 | ALDH1A1 (0.74) | ALDH1A1CYP3A4TSHRTDP1HSD17B10 | |
| SCHEMBL28170408 | 0.81 | CA2 (0.68) | ALDH1A1CYP3A4CYP19A1NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | CONTINEUM THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-118146115-B | Azo compound, azo prodrug compound, pharmaceutical composition, high-energy-ray-responsive lipid molecule, and high-energy-ray-responsive liposome | 中科帅天医药(深圳)有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-118146115-A | Azo compound, azo prodrug compound, pharmaceutical composition, high-energy-ray-responsive lipid molecule, and high-energy-ray-responsive liposome | 中科帅天医药(深圳)有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2023014907-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023014907-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022255425-A1 | CONJUGATE OF ANTIBODY AND FUNCTIONAL SUBSTANCE OR SALT OF SAID CONJUGATE, AND COMPOUND FOR USE IN PRODUCTION OF SAID CONJUGATE OR SALT OF SAID COMPOUND | 味の素株式会社 | 2022-12-08 | — | — | WO | disclosed |
| US-6194396-B1 | ANTIALLERGENS; ANTIINFLAMMATION AGENTS; AUTOIMMUNE DISEASE; ANTISHOCK AGENTS; ANALGESICS; E.G., A 4 OR 7-PHENYLALKYLENE-OXYBENZIMIDAZOLE UNSUBSTITUTED OR SUBSTITUTED IN THE 1,2,3-POSITION WITH AN OXY, AMINO AND/OR THIO GROUP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| US-6100284-A | ANTIALLERGENS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| US-6083961-A | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES SUCH AS ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| US-6008229-A | TREATING ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
| US-5994368-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0861243-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-09-02 | — | — | EP | disclosed |
| EP-0807105-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| EP-0774462-A1 | HETEROCYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| WO-1997011069-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-27 | — | — | WO | disclosed |
| WO-1996013485-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR3 | ALDH1A1 1523/4885CYP3A4 4412/4885TSHR 252/4885 |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | ALDH1A1 1060/4885CYP3A4 4060/4885TSHR 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.